Previous Close | 2.1500 |
Open | 2.1000 |
Bid | 0.0000 x 38800 |
Ask | 0.0000 x 28000 |
Day's Range | 2.0970 - 2.5700 |
52 Week Range | 1.1500 - 9.6300 |
Volume | |
Avg. Volume | 10,324,920 |
Market Cap | 995.702M |
Beta (5Y Monthly) | 2.43 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5270 |
Earnings Date | May 11, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for SRNE
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services (“HHS”)
Shares of small-cap biotech Sorrento Therapeutics (NASDAQ: SRNE) were up by a noteworthy 13.3% on heavy trading volume as of 11:24 a.m. ET Tuesday. What's particularly interesting about this double-digit percentage move is that the company hasn't announced any significant material events in about a month. The biotech stock shed an eye-catching 56% of its value amid that downturn.
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services (“HHS”) and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento’s Chairman and CEO Henry Ji. G